March 18, 2009

CENTER FOR VETERINARY BIOLOGICS NOTICE NO. 09-04

TO: Veterinary Services Management Team
    Directors, Center for Veterinary Biologics
    Biologics Licensees, Permittees, and Applicants

FROM: Richard E. Hill, Jr. /s/ Byron Rippke, for
    Director
    Center for Veterinary Biologics

SUBJECT: Conversion Formulas for S/P Ratio to Titer in Diagnostic Test Kit Inserts

I. PURPOSE

The purpose of this memorandum is to provide guidance to interested parties for relating
the response obtained in an ELISA immunodiagnostic kit to a titer.

II. BACKGROUND

Antigen/antibody-based immunodiagnostic test kits for the diagnosis of animal disease
are evaluated by the Center for Veterinary Biologics (CVB) as authorized by Title 9 Code
of Federal Regulations, Part 114.9(f). Typically, immunodiagnostic kits are designed to
differentiate positive from negative individuals by the response of their sera in the kit. In
many kits, a continuous response is recorded; and the response is then dichotomized
using a cut-off point such that values on one side are designated positive and those on
the other are negative.

The sample-to-positive ratio (S/P) in an enzyme-linked immunosorbent assay (ELISA) is
such a response. A predetermined single dilution of an unknown serum specimen is
applied to the plate and the response measured, usually as optical density (OD). This is
compared to the response of a reference serum, the positive control (PC). The final value
that is calculated is the S/P, the ratio of the unknown’s OD to the PC’s OD, after
correcting both for a blank or negative control.

The instructions for some commercial immunodiagnostic kits contain a formula giving a
linear transformation of S/P or log(S/P) to serum titer, for example:

\[ \log \text{(titer)} = a + b \log(S/P) \]

A serum titer, defined as the reciprocal of the greatest dilution in a dilution sequence that
produces a response, is valuable when it reflects a meaningful immunological event, such
as virus neutralization or hemagglutination. In the absence of such an event, an arbitrary response threshold may be set, below which the response is deemed negative (cut-off point). Commercial diagnostic kit ELISA titers defined in that way refers only to the test itself and is not directly related to a meaningful immunological event.

The S/P is intended to be a yes or no response that designates a specimen as positive or negative by comparing it to a reference serum. By itself, S/P is not quantitative and not a titer.

Since a binary response is all that is necessary for diagnostic purposes, designing diagnostic assays for S/P is a convenience and only requires a single dilution rather than a dilution series. Usually the S/P-titer relationship is not linear and varies depending on the dilution that is selected for use in the assay. However, if the conditions are defined and one makes certain assumptions, the relationship between titer or log (titer) and S/P may be approximately linear.

Under these conditions the S/P may be a crude guide to antibody titer and included in the product literature, provided the relationship is justified. This may be included in product literature under the following conditions.

III. ACTION

For new products seeking licensure and currently licensed products wishing to add a formula for conversion of the S/P to titer to the product insert, the formula must be supported by data from appropriate dilution sequences.

Existing products that already have a conversion formula in the product insert may continue to use the conversion formula.

The product insert of all products with a conversion formula should indicate the following:

- The S/P is intended as a diagnostic response to differentiate positive from negative serum specimens.
- The conversion formula may give a rough indication of the specimen’s antibody titer. For accurate quantitative assessment, conduct a titration with a dilution sequence.
- The relationship between immunity and either S/P or antibody titer has not been established for this product.

This information may be included in the product literature but may not be used as the criteria for serial release or as validity criterion for establishing that a test run is valid. A consistent formula and positive control are essential in order to compare test results from
one time period to another when using the same test kit. Therefore, the formula should not change, and criteria for accepting a new positive control must be established.